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ABSTRACT
Aims: We aimed to investigate the clinical significance of GPx3 in hepatocellular 
carcinoma (HCC) and to characterize its tumor suppressive role.
Methods: HCC patients (113) who underwent hepatectomy were recruited to 
examine the clinical relevance of GPx3. The tumor suppressive role of GPx3 was 
studied by administration of recombinant GPx3 (rGPx3) or over-expression of GPx3 
in HCC cells in vitro and in vivo. The therapeutic value of GPx3 for HCC was further 
investigated using human induced pluripotent stem cell derived mesenchymal stem 
cells (hiPSC-MSCs) as its delivery vehicle.
Results: Down-regulation of GPx3 significantly correlated with advanced 
tumor stage (P = 0.024), venous infiltration (P = 0.043) and poor overall survival  
(P = 0.007) after hepatectomy. Lower plasma GPx3 in HCC patients was significantly 
associated with larger tumor size (P = 0.011), more tumor nodules (P = 0.032) and 
higher recurrence (P = 0.016). Over-expression of GPx3 or administration of rGPx3  
significantly inhibited proliferation and invasiveness of HCC cells in vitro and 
in vivo. Tumor suppressive activity of GPx3 was mediated through Erk-NFκB-SIP1 
pathway. GPx3 could be delivered by hiPSC-MSCs into the tumor and exhibited tumor 
suppressive activity in vivo.
Conclusions: GPx3 is a tumor suppressor gene in HCC and may possess prognostic 
and therapeutic value for HCC patients.
INTRODUCTION
Oxidative stress is fatal to normal cells. In contrast, 
it plays a key role in cell survival and proliferation of 
several types of cancer [1]. Unlimited proliferation of 
cancer cells, to some extent, relies on intracellular oxidants 
such as reactive oxygen species (ROS). Oxidative stress 
could cause genetic mutation [2], up-regulate signaling 
pathways that control cell survival and invasiveness [3] 
and provide favorable micro-environment for cancer 
development [4]. Therefore, attenuation of oxidative 
stress post-operation or combined with chemotherapy may 
provide new insights for cancer treatment.
Glutathione peroxidase 3 (GPx3) was found to be 
up-regulated in acute phase injury as an anti-oxidant to 
protect the organ from oxidative stress by detoxifying 
hydrogen peroxide and other free radicals [5, 6]. It has also 
been noticed that expression of GPx3 is significantly down-
regulated within tumor tissues in several types of cancers. 
The mRNA level of GPx3 is down-regulated in esophageal 
squamous cell carcinoma due to epigenetic silence [7]. 
The down-regulation of GPx3 was also observed in 
Barrett’s adenocarcinoma because of DNA methylation 
[8]. Much lower expression levels of GPx3 were observed 
in colorectal cancer compared with non-tumor tissues [9]. 
Besides the down-regulation of GPx3 within tumor tissues, 
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the circulating GPx3 was also found to be much lower in 
the patients with glioblastoma than non-patients which 
implies that it may possess the prognostic value for cancer 
patients [10]. Although the down-regulation of GPx3 was 
shown in several malignancies, the clinical significance 
and functional role of GPx3 in cancer development have 
not been well illustrated.
Hepatocellular carcinoma (HCC) is the sixth most 
common cancer and ranks as high as third for cancer-
related deaths worldwide [11]. Although tumor resection 
and liver transplantation are effective treatments for 
selected HCC patients, tumor recurrence remains a main 
concern [12–14]. Furthermore, surgical treatment is not 
applicable for patients with advanced tumor stages [15–18]. 
Development of a new approach to prevent tumor 
recurrence and improve prognosis is an urgent need for 
HCC patients. The role of anti-oxidant in treatment of 
HCC patients has not been illustrated. So far, there is no 
information about the role of GPx3 in HCC. Exploration 
of functional role of GPx3 in HCC could provide new 
evidences to apply anti-oxidant agents for cancer therapy.
Firstly, we examined the clinical significance of 
GPx3 in HCC patients and found that lower expression of 
GPx3 in tumors could predict the advanced tumor stage 
and higher probability of tumor recurrence. Secondly, 
we explored the tumor suppressive activity of GPx3 
in vitro by administration of rGPx3 or forced expression 
of GPx3 in different liver cancer cell lines. Thirdly, we 
demonstrated the anti-tumor effect of GPx3 in vivo using 
ectopic and orthotopic liver cancer models. Fourthly, we 
found that the tumor suppressive activity of GPx3 was 
mediated by inhibition of EMT (Epithelial-Mesenchymal 
Transition) through Erk-NFκB-SIP1 signaling pathway. 
Finally, we explored the therapeutic value of GPx3 for 
HCC using hiPSC-MSCs as a delivery vehicle. This is the 
first study to suggest the prognostic and therapeutic value 
of GPx3 in HCC patients.
RESULTS
Expression of GPx3 was down-regulated within 
tumor tissues in HCC patients
The average mRNA level of GPx3 was significantly 
lower within tumor tissues compared with adjacent non-
tumor tissues and normal liver tissues (Fig. 1A, left panel). 
The down-regulation of GPx3 in tumor tissues compared 
with adjacent non-tumor tissues was observed in 50% 
of HCC patients (56/113). It seemed that the difference 
between normal and diseased samples were larger than that 
between tumor and non-tumor tissues (Fig. 1A, left panel). 
There are two possible explanations. On one hand, HCC is 
regarded as inflammation associated cancer, which always 
develops with the background of cirrhosis. In such types 
of cancer, the chronic inflammation is always inevitable 
and would cause the lower level of GPx3 expression. 
On the other hand, the adjacent non-tumor tissue could 
be generally perceived as “pre-cancer” disease. Our 
results showed that GPx3 was already significantly 
down-regulated in such “pre-cancer” tissues. It implied 
that down-regulation of GPx3 may not only be involved 
in tumor progression, but also tumor development or 
carcinogenesis. Consistent with mRNA levels, the protein 
levels of GPx3 were also found down-regulated in tumor 
tissues (Fig. 1B). IHC staining also confirmed that lower 
expression of GPx3 was detected within tumor tissues 
(Fig. 1C).
Down-regulation of GPx3 mRNA significantly 
correlated with advanced tumor stage and poor 
prognosis in HCC patients
The association of GPx3 mRNA with 
clinicopathological parameters was analyzed (Table 1). 
Down-regulation of GPx3 was significantly correlated 
with advanced pTNM stage (P = 0.024), presence of 
venous infiltration (P = 0.043) and high AFP level 
(P = 0.006). The five year recurrence (P = 0.019) was 
significantly higher in the patients with GPx3 down-
regulation. No significant association of GPx3 expression 
was detected with sex, age, tumor size, number of tumor 
nodules and presence of hepatitis B surface antigen.
Kaplan-Meier survival analysis showed that the 
down-regulation of GPx3 mRNA was significantly 
correlated with poor overall survival of HCC patients 
(Log rank = 7.297, P = 0.007, Fig. 1A, right panel). The 
estimated mean overall survival time of the patients with 
GPx3 down-regulation was 58.72±6.94 months, which 
was significantly lower than that of patients without GPx3 
down-regulation (86.46±6.85 months). The independent 
predictor for overall survival was further identified 
among GPx3, pTNM stage, venous infiltration and 
AFP using Cox proportional hazard regression analysis 
(Table S1). In univariable analysis, down-regulation of 
GPx3 (HR=2.084, 95%CI: 1.209–3.593, P = 0.008) was 
significantly associated with overall survival. However, 
in multivariable analysis, only venous infiltration 
(HR=3.003, 95%CI: 1.259–7.160, P = 0.013) was 
identified as an independent predictor.
Lower plasma GPx3 significantly correlated with 
tumor progression and tumor recurrence  
in HCC patients
The area under the ROC curve of plasma GPx3 
was 0.643 (0.534–0.751) for prediction of five year 
recurrence. The value (4.842µg/mL) with a maximized 
Youden index was selected as the cutoff point by which 
all the patients were segregated into two groups: low and 
high level group. The larger tumor size (P = 0.011) and 
higher number of tumor nodules (P = 0.032) were found 
in the GPx3 low level group. The five year recurrence rate 
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Figure 1: Down-regulation of GPx3 in HCC patients. (A) GPx3 mRNA in clinical samples (Left panel), *P < 0.05, **P < 0.01. 
Overall survival of HCC patients underwent hepatectomy (Right penal), *P < 0.05. (B) Representative images of down-regulation of GPx3 
in tumor tissues compared with adjacent non-tumor tissues by Western-Blot. (C) Representative images of HE staining showing the down-
regulation of GPx3 within tumor tissue (400×).
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Table 1: The correlation of GPx3 expression with clinical parameters of HCC patients
Clinicopathological features
GPx3 expression level (n)




0.210 Male 92 43 49
 Female 21 13 8
Age
0.926 Younger than 55 57 28 29
 Older than 55 56 28 28
pTNM stagea
0.024 * Early stage (1-2) 29 9 20
 Advanced stage (3-4) 83 46 37
Venous infiltration
0.043 * Absent 47 18 29
 Present 66 38 28
Tumor sizea
0.462 Less than 5 cm 47 25 22
 More than 5 cm 65 30 35
Tumor Nodulesa
0.448 Less than 3 83 39 44
 More than 3 29 16 13
HBsAg
0.794 Negative 13 6 7
 Positive 100 50 50
AFP levela
0.006* Lower than 20 ng/mL 45 15 30
 Higher than 20 ng/mL 67 40 27
One year recurrencea
0.038* Recurrence 42 27 15
 Non-recurrence 62 27 35
Five year recurrencea
 0.019* Recurrence 62 36 26
 Non-recurrence 43 15 28
aThe total number less than 113 due to missing data.
*Significant difference.
(P = 0.016) was significantly higher in the patients with 
low plasma GPx3 (Table 2). No significant association of 
plasma GPx3 was detected with age, sex, pTNM stage, 
venous infiltration and hepatitis B surface antigen. The 
patients with low plasma GPx3 had relatively shorter 
disease-free survival period (35.37±6.22 vs 49.14±7.11 
months). However, the difference did not reach statistical 
significance (Log rank=2.044, P = 0.153).
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Table 2: The correlation of plasma GPx3 with clinical parameters of HCC patients
Clinicopathological features
Plasma GPx3 level (n)
P
Number Low levelb High levelb
Sex
0.835 Male 88 44 44
 Female 19 9 10
Age
0.210 Younger than 55 52 29 23
 Older than 55 55 24 31
pTNM stagea
0.353 Early stage (1-2) 24 10 14
 Advanced stage (3-4) 82 43 39
Venous infiltration
0.750 Absent 42 20 22
 Present 65 33 32
Tumor sizea
 0.011* Less than 5 cm 45 16 29
 More than 5 cm 61 37 24
Tumor Nodulesa
 0.032* Less than 3 77 34 43
 More than 3 28 19 9
HBsAg
0.518 Negative 12 7 5
 Positive 95 46 49
AFP levela
0.691 Lower than 20 ng/mL 42 22 20
 Higher than 20 ng/mL 64 31 33
One year recurrencea
0.227 Recurrence 42 24 18
 Non-recurrence 60 27 33
Five year recurrencea
 0.016* Recurrence 61 36 25
 Non-recurrence 38 13 25
aThe total number less than 107 due to missing data.
bThe cutoff point with maximized Youden index was 4.842µg/mL by which all the patients were segregated into 
two groups.
*Significant difference.
Expression level of GPx3 in normal and 
HCC cell lines
The mRNA level of GPx3 was significantly 
lower in HCC cell lines (except HepG2) compared 
with immortalized liver cell lines (MIHA and LO2) 
(Fig. 2A). Among HCC cell lines, the expression of 
GPx3 was significantly lower in metastatic HCC cell line 
(MHCC97L) compared with non-metastatic HCC cell 
lines (Hep3B and Huh7).
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Recombinant GPx3 protein (rGPx3) or  
over-expression of GPx3 inhibited proliferation 
and invasiveness of HCC cells in vitro
Administration of rGPx3 inhibited the proliferation 
of MHCC97L, Hep3B and Huh7, whose GPx3 was 
relatively low (Fig. 2B). The proliferation of HCC 
cells was most significantly suppressed by rGPx3 at 
the concentration of 2µg/mL, which was shown to be 
non-toxic to normal liver cells (MIHA) (Fig. 2B). The 
invasiveness of MHCC97L, Hep3B and Huh7 was also 
suppressed by administration of rGPx3 (Fig. 2C). The 
number of migrated cells was significantly lower upon 
rGPx3 administration in the Matrigel invasion assay 
(Fig. 2D).
Over-expression of GPx3 was established in 
Huh7 and MHCC97L. The clones with the highest 
expression of GPx3 were picked up for further 
investigation (Fig. S1A and B). We also confirmed that 
secreted GPx3 was significantly increased in the culture 
medium after transfection (Fig. 3A). It implied that the 
forcedly expressed GPx3 could be successfully secreted 
extracellularly. Over-expression of GPx3 significantly 
inhibited the proliferation (Fig. 3B) of Huh7 and 
MHCC97L in MTT assay. Moreover, in colony formation 
assay, the colony number and size were both significantly 
lower in GPx3 over-expression group (Fig. 3C). 
Furthermore, the invasiveness was also significantly 
suppressed by over-expression of GPx3 in Huh7 and 
MHCC97L (Fig. 3D).
Over-expression of GPx3 suppressed tumor 
growth and invasiveness in vivo
In nude mice ectopic liver cancer model, the tumor 
growth rate of MHCC97L-GPx3-2 was significantly lower 
compared with vector control (Fig. 4A and B). In nude 
mice orthotopic liver cancer model, tumor volume was 
significantly lower in MHCC97L-GPx3-2 group (Fig. 4C). 
The over-expression of GPx3 in MHCC97L-GPx3-2 group 
was also confirmed 5 weeks after tumor implantation 
(Fig. 4D). It implied that forced-expression of GPx3 could 
be sustained in vivo and secreted extracellularly. A relatively 
clear margin between tumor and adjacent non-tumor 
tissues was found in the MHCC97L-GPx3-2 group. On the 
contrary, invasive patterns of tumor growth were present in 
vector control group (Fig. 4E). The results showed that over-
expression of GPx3 suppressed tumor invasiveness in vivo.
GPx3 inhibited Epithelial-Mesenchymal 
Transition (EMT) through suppression of Smad 
Interacting Protein 1 (SIP1)
As significant anti-invasiveness effect of GPx3 
was observed in vitro and in vivo (Fig. 2C, 3D and 4E), 
we further investigated the effect of GPx3 on EMT 
process. GPx3 significantly inhibited EMT which was 
stimulated by TGF-β in MHCC97L (Fig. 5A). GPx3 
restored the expression of E-cadherin (epithelial marker) 
and decreased expression of Vimentin (mesenchymal 
marker) of MHCC97L.
In order to further investigate the underlying 
mechanism of inhibitory effect of GPx3 on EMT, several 
transcriptional repressors of E-cadherin that are commonly 
involved in EMT process, such as Slug, Snail, Zeb1, SIP1 
and Twist, were selected for detection. In our case, SIP1 
was shown to be most significantly suppressed by GPx3 
treatment independent of TGF-β stimulation (Fig. 5B).
GPx3 suppressed SIP1 expression through 
inhibition of Nuclear Factor κB (NFκB) 
activation
NFκB was reported to be directly involved in EMT 
process and is the key mediator for SIP1 expression [19]. 
In our study, SIP1 expression could be regulated by NFκB 
pathway as administration of specific NFκB inhibitor 
(PDTC) suppressed SIP1 expression (Fig. 5C, left panel). 
Furthermore, NFκB nuclear translocation was significantly 
attenuated upon rGPx3 administration, indicating that 
activation of NFκB could be inhibited by GPx3 treatment 
(Fig. 5C, right panel). Thus, GPx3 treatment might inhibit 
NFκB activation, which would further suppress SIP1 
expression.
GPx3 inhibited NFκB activation through 
deactivation of Extracellular signal-regulated 
kinase (Erk)
PI3K-AKT and Ras-MEK-Erk signaling 
pathways are both commonly involved in liver cancer 
progression and are reported to be the activators of 
the NFκB signaling pathway [20, 21]. In our case, the 
activated form of AKT remained unchanged upon rGPx3 
administration (Fig. S2A). However, significant inhibition 
of Erk activation was observed upon rGPx3 administration 
(Fig. 5D, left panel). Furthermore, activation of NFκB 
could be regulated by the Erk pathway as evidenced by 
how the administration of specific Erk inhibitor (U0126) 
deactivated NFκB-p65 (Fig. 5D, right panel). Thus, 
GPx3 might inhibit Erk activation, which would further 
deactivate NFκB signaling pathway. The same trend could 
also be observed in orthotopic liver cancer model that 
activation of NFκB was inhibited by the over-expression 
of GPx3 through deactivation of Erk (Fig. 5E).
GPx3 deactivated Erk by up-regulation of MAP 
Kinase Phosphatase 3 (MKP3)
We further observed that the activation of Erk could 
be inhibited by GPx3 in a dose dependent manner (Fig. 5F, 
left panel). However, the up-stream stimulators of the 
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Figure 2: Effects of rGPx3 on HCC cells. (A) GPx3 mRNA in different cell lines, *P < 0.05 vs MIHA and LO2; #P < 0.05 vs Hep3B 
and Huh7. (B) The effect of rGPx3 on proliferation of different cells, *P < 0.05 vs 0 µg/mL. (C and D): The effect of rGPx3 on invasiveness 
of HCC cells.
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Figure 3: Effects of over-expression of GPx3 on HCC cells. (A) Secreted GPx3 in culture medium. (B) MTT assay, *P < 0.05. 
(C) Colony formation assay, *P < 0.05. (D) Matrigel invasion assay, *P < 0.05.
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Figure 4: Effects of over-expression of GPx3 on tumor growth in nude mice ectopic and orthotopic liver cancer 
model. (A and B) Over-expression of GPx3 significantly inhibited subcutaneous tumor growth, *P < 0.05. (C) Over-expression of GPx3 
significantly inhibited orthotopic tumor growth, *P < 0.05. (D) Over-expression of GPx3 could be maintained 5 weeks after implantation. 
(E) Representative images of HE staining (400×).
Oncotarget11112www.impactjournals.com/oncotarget
Figure 5: Potential mechanism for tumor suppressive activity of GPx3. (A) GPx3 inhibited EMT in MHCC97L. (B) GPx3 
inhibited EMT through suppression of SIP1. (C) GPx3 suppressed expression of SIP1 through inhibition of NFκB nuclear translocation 
(right panel). SIP1 expression could be regulated by NFκB pathway evidenced by effect of specific NFκB inhibitor (PDTC, left panel). 
(D) GPx3 inhibited activation of NFκB through deactivation of Erk (left panel). Activation of NFκB could be regulated by Erk pathway 
evidenced by effect of specific Erk inhibitor (U0126, right panel). (E) Deactivation of NFκB and Erk by GPx3 was confirmed in orthotopic 
tumor model. (F) GPx3 inhibited Erk activation in a dose dependent manner and attenuated EGF- and HGF- induced Erk activation through 
restoration of MKP3 expression. (G) Expression of MKP3 in MHCC97L was negatively regulated by H2O2.
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Erk signaling pathway, such as Raf and MEK, were not 
changed upon GPx3 treatment (Fig. S2A). It implied that 
deactivation of Erk by GPx3 may not be mediated through 
Raf-MEK pathway. It was reported that the negative 
feedback of Erk activation was regulated by MKP3 [22], 
which was Erk phosphatase and widely expressed in liver 
tissue. In our case, MKP3 was significantly up-regulated 
upon rGPx3 treatment in a dose dependent manner (Fig. 5F, 
left panel). Furthermore, GPx3 could attenuate EGF 
(Epidermal Growth Factor) and HGF (Hepatocyte Growth 
Factor) induced Erk activation through the restoration of 
MKP3 expression (Fig. 5F, right panel). Thus, the inhibitory 
effect of GPx3 on Erk activation might be mediated through 
up-regulation of MKP3, which could maintain the negative 
feedback loop of Erk activation (Fig. S3). Moreover, our 
study showed that expression of MKP3 could be negatively 
regulated by H2O2 level (Fig. 5G). Thus, the restoration of 
MKP3 expression by GPx3 might be mediated through 
elimination of H2O2 due to the detoxification of GPx3.
Engineered hiPSC-MSCs delivering 
GPx3 was established
In order to explore the therapeutic value of GPx3 using 
hiPSC-MSCs as a delivery vehicle in HCC, we established 
the engineered hiPSC-MSCs delivering GPx3. Full length 
of human GPx3 gene was transduced into the hiPSC-MSC 
cell line [23]. The transduction efficiency was confirmed to 
be nearly 100% (Fig. S4A). The protein level of intracellular 
GPx3 and secreted GPx3 in culture medium were both 
confirmed to be significantly elevated after transduction 
(Fig. S4B). The stem cell property of hiPSC-MSCs was still 
maintained after transduction as evidenced by positive and 
negative markers detected using flow cytometry (Fig. S5).
Engineered hiPSC-MSCs delivering GPx3 
significantly suppressed tumor growth in vitro
The significant inhibitory effect of hiPSC-MSC-
GPx3 on the proliferation of MHCC97L cells was 
observed when the cell number ratio reached 2:1 or 1:1 
(MHCC97L:hiPSC-MSC-GPx3) in MTT assay (Fig. 6A). 
In order to avoid the influence of proliferation of hiPSC-
MSCs in detection, hiPSC-MSC-GPx3 was co-cultured 
with MHCC97L cells labeled with luciferase (Fig. 6B). 
The bioluminescence of MHCC97L was significantly 
lower in the hiPSC-MSC-GPx3 group. It implied that 
hiPSC-MSC-GPx3 could significantly suppress the 
proliferation of MHCC97L cells (Fig. 6C).
Engineered hiPSC-MSCs delivering GPx3 
significantly suppressed tumor growth in vivo
The subcutaneous tumor growth curve was 
significantly lower in the hiPSC-MSC-GPx3 treatment 
group (Fig. 7A). In the orthotopic model, the tumor 
volume was significantly lower in the hiPSC-MSC-GPx3 
treatment group when nude mice were sacrificed (Fig. 7B). 
The kinetic images of tumor growth also showed that 
hiPSC-MSC-GPx3 treatment significantly suppressed 
orthotopic tumor growth in vivo (Fig. 7C). According 
to immunoflorescence and IHC staining, human hiPSC-
MSCs could be traced within tumor tissues (Fig. 7D, 
middle panel). Moreover, GPx3 expression could be 
detected at the same area at which hiPSC-MSC-GPx3 
cells were located (Fig. 7D, lower panel). It implied that 
GPx3 could be successfully delivered by hiPSC-MSCs 
into tumor tissues.
DISCUSSION
We demonstrated that the lower plasma GPx3 
indicated tumor recurrence and shorter disease-free-
survival period of HCC patients after liver resection. 
The down-regulation of GPx3 within tumor tissue also 
significantly correlated with advanced tumor stage and 
appearance of venous infiltration in HCC patients. These 
findings implied that GPx3 may possess prognostic value 
to predict HCC progression and recurrence. Although 
numerous biomarkers have been studied in past decades, 
the serological detection of HCC recurrence mainly relies 
on the traditional marker AFP [4, 24]. However, the 
positive predictive value (PPV) of AFP is not satisfied 
[25]. Furthermore, as the secreted proteins originated 
from tumors, AFP does not possess therapeutic value for 
HCC patients. So far, there is no promising biomarker 
possessing both prognostic and therapeutic value for HCC 
patients. In addition to indicating the clinical significance 
of GPx3, we also illustrated that over-expression of GPx3 
in HCC cells significantly suppressed tumor proliferation 
and invasiveness in vitro and in vivo. More importantly, 
we demonstrated, for the first time that the tumor 
suppressive activity of GPx3 delivered by hiPSC-MSCs 
indicated the therapeutic potential of hiPSC-MSC-GPx3 
for HCC patients. Based on the advantages that patient 
specific hiPSC-MSCs could be prepared as an “off-the-
shelf” source with a higher capacity of self-renewal 
and engraftment [23], the clinical application of hiPSC-
MSC-GPx3 may be a practical choice to prevent tumor 
recurrence and improve prognosis of HCC patients after 
liver surgery.
Epigenetic hypermethylation and genome deletion 
are reported as two reasons for the down-regulation of 
GPx3 during cancer development [7, 8, 26, 27], but the 
mechanism of down-regulation of GPx3 contributing to 
tumor progression remains to be investigated. GPx3 has 
been reported to commit its tumor suppressive activity 
through inhibition of c-Met expression in prostate cancer 
[28]. However, we did not find any difference of c-Met 
expression in HCC cell lines with forced expression of 
GPx3 (Fig. S2B). It indicated that tumor suppressive 
activity of GPx3 through down-regulation of c-Met may be 
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Figure 6: Tumor suppressive activity of hiPSC-MSC-GPx3 in vitro. (A) hiPSC-MSC-GPx3 significantly inhibited proliferation 
of MHCC97L in MTT assay, *P<0.05. (B and C) hiPSC-MSC-GPx3 significantly inhibited proliferation of MHCC97L shown by 
bioluminescence, *P<0.05.
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Figure 7: Tumor suppressive activity of hiPSC-MSC-GPx3 in vivo. (A) Subcutaneous tumor growth curve was significantly 
lower in hiPSC-MSC-GPx3 group. (B) Orthotopic tumor volume was significantly lower in hiPSC-MSC-GPx3 group. (C) Kinetic 
images of tumor growth showed tumor suppressive activity of hiPSC-MSC-GPx3, *P<0.05. (D) Successful delivery of GPx3 by hiPSC-
MSCs in tumor tissues. Pictures in each group showed the same area of tissue sections (400×).
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cell-type-specific. Moreover, several reports demonstrated 
that the tumor suppressive function of GPx3 was mediated 
through induction of apoptosis in prostate and colon cancer 
[29, 30]. However, in our study, no significant effect of 
GPx3 on apoptosis of HCC cells was observed (Fig. S1C). 
Consistently, we did not find any change in cell survival 
pathway, such as AKT pathway, after over-expression 
of GPx3 (Fig. S2A). It implied that other underlying 
mechanism might be existed for tumor suppressive activity 
of GPx3 in liver cancer. This is the first study to show that 
rGPx3 suppressed invasiveness of HCC cells by inhibition 
of EMT through Erk-NFκB-SIP1 signaling pathway. 
It has been reported that activation of NFκB could be 
determined by the Erk pathway [31]. It was consistent 
with our results. In addition, the regulatory effect of 
NFκB on SIP1 expression is also supported by Julien, 
who demonstrated that activation of NFκB promotes SIP1 
expression which further suppresses E-cadherin expression 
[32]. We identified that only inhibition of SIP1, among five 
E-cadherin transcriptional repressors, was responsible 
for restoration of E-cadherin by rGPx3. So far, there is 
no promising SIP1 inhibitor for cancer therapy except 
for epigenetic silencing [33], in which the negative side 
effects may be inevitable. Besides that, the application 
of inhibitors of the NFκB pathway for cancer therapy is 
still at an early stage because of several severe side effects 
[34]. The hiPSC-MSC-GPx3 treatment with property of 
tumor tropism may be prospective for clinical utilization 
of cancer target therapy in HCC patients.
In addition to anti-invasiveness, significantly 
inhibitory effect of GPx3 or hiPSC-MSC-GPx3 on 
proliferation of HCC cells was also observed in vitro and 
in vivo. We found that GPx3 could maintain negative 
feedback of Erk activation by up-regulation of MKP3, 
which further deactivated the NFκB pathway. The inhibitory 
effect of GPx3 on Erk-NFκB activation might be able to 
explain the suppressive effect of GPx3 on both proliferation 
and invasiveness of HCC cells. This was confirmed in our 
animal model (Fig. 5E). Further research is required to 
understand whether there are other potential mechanisms 
involved in the tumor suppressive activity of GPx3.
Engineered MSC with an anti-tumor agent was 
reported as a novel strategy for cancer therapy with 
the advantage of fewer systemic side effects [35, 36]. 
However, the self-renewal capacity of bone-marrow-
derived-MSCs (BM-MSCs) was significantly deteriorated 
with aging [37]. The hiPSC-MSCs were discovered to 
possess a higher capacity of self-renewal with telomerase 
activity 10-fold higher than BM-MSCs [23]. Thus, it was 
of our great interest to explore the therapeutic value of 
GPx3 using hiPSC-MSCs as a delivery vehicle for HCC. 
The co-localization of hiPSC-MSCs and GPx3 expressions 
detected within tumor tissues highly implied that GPx3 
can be successfully delivered by hiPSC-MSCs into the 
tumor site. This finding might provide a new delivery 
strategy for GPx3 in liver cancer target therapy.
We suggested that the lower circulating GPx3 
possessed prognostic value for HCC patients. We not 
only investigated the clinical significance, but also further 
demonstrated the tumor suppressive role of GPx3 in HCC 
in vitro and in vivo. Moreover, we discovered the potential 
mechanism of GPx3 that suppressed invasiveness of tumor 
by inhibition of EMT through the Erk-NFκB-SIP1 signaling 
pathway. Most importantly, we further demonstrated 
therapeutic value of GPx3 using hiPSC-MSCs as a delivery 
vehicle in liver cancer models. Further investigation is 
required to explore the therapeutic effect of hiPSC-MSC-
GPx3 combined with other anti-tumor agents.
MATERIALS AND METHODS
Study design
The flow diagram of study design is shown in 
Fig. S6. In clinical association study, the correlation 
of GPx3 expression with clinicopathological features 
and survival outcome were investigated in 113 HCC 
patients, who had undergone hepatectomy. In functional 
study, the effects of GPx3 on HCC cells were examined 
by administration of rGPx3 and forced expression of 
GPx3 in HCC cells in vitro, and the in vivo role of GPx3 
was explored in ectopic and orthotopic xenograft liver 
cancer models. In mechanism study, effects of GPx3 on 
the EMT process and the activation of Erk-NFκB-SIP1 
pathway were further explored. In translational study, the 
therapeutic value of GPx3 in HCC was explored using 
hiPSC-MSCs as a delivery vehicle in vitro and in vivo.
Clinical association study
Clinical specimens
The study was approved by the Institutional 
Review Board of the University of Hong Kong / Hospital 
Authority Hong Kong West Cluster. 113 HCC patients 
who had undergone curative partial hepatectomy 
between November 1999 and May 2009 were recruited 
with informed consent from the Department of Surgery, 
Queen Mary Hospital, The University of Hong Kong. All 
the patients were diagnosed with primary HCC and the 
patients with severe systemic disorder or combined with 
other tumors were excluded from the study. The median 
of follow up time was 6 years (2 months–11 years). The 
median age of the patients was 55 (22–81) years old. 
Eighty one percent of patients were male. Eighty eight 
percent of patients were HBsAg positive. One hundred 
and thirteen pairs of fresh tumor tissue and adjacent non-
tumor tissue samples were collected from HCC patients 
and 10 normal liver tissue samples were collected from 
donors during operation. One hundred and seven plasma 
samples were collected within a week pre-operation.
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Real time quantitative reverse transcription polymerize 
chain reaction (qRT-RCR), Immunohistochemistry 
(IHC) and Western-Blot
The mRNA level of GPx3 was determined by 
qRT-PCR. The protein level of GPx3 was detected by 
IHC and Western-blot as previously described [38]. GPx3 
primary anti-body (Abcam) was used in immunostaining. 
The sequences of primers used were recorded (Table S2).
Enzyme-linked immunosorbent assay (ELISA)
The plasma samples were diluted 800 times and the 
medium for cell culture was without any dilution before 
detection. The concentration of GPx3 was tested using 
ELISA kit according to instruction manual (AdipoGen Inc, 
Incheon, Korea).
In Vitro functional study
Cell culture, transfection and stable cell lines
Human liver cancer cell lines (HepG2, Hep3B 
and Huh7) and human immortal liver cell lines (MIHA 
and LO2) were purchased from the American Type 
Culture Collection (Manassas, VA, USA). The 
metastatic human liver cancer cell line MHCC97L was 
obtained from the Liver Cancer institute and Zhongshan 
Hospital of Fudan University, Shanghai, the People’s 
Republic of China [39]. All the cell lines were cultured 
as previously described [40]. The pcDNA 3.1 (+) 
vector was purchased from Invitrogen (Carlsbad, CA). 
MHCC97L and Huh7 cells were transfected with 
recombinant plasmid using lipofectamine 2000 Reagent 
(Invitrogen, Carlsbad, CA) and cultured for two weeks 
under G418 selection. Stable clones were maintained 
in 0.05 mg/mL G418 for Huh7 cells and 0.5 mg/mL for 
MHCC97L cells, respectively.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay and Colony formation assay
In order to explore the proliferation rate of HCC 
cells, MTT and colony formation assay were performed 
as previously described [40].
Matrigel invasion assay
Around 5 × 104 cells were seeded into the upper 
chamber (BD Biosciences) in 0.5 ml of serum-free 
DMEM. In the meantime, the lower chamber was filled 
up using DMEM with 10% FBS as a chemoattractant. 
The cells were incubated at 37°C with 5% CO2 for 
24h for Huh7 and 48h for MHCC97L, respectively. 
After that, cells left on the upper surface of the chamber 
were removed gently using a cotton tip. Cells that had 
penetrated through the membrane of chamber were 
fixed by methanol at -20ºC for 20min, stained with 
0.1% crystal violet for 1h and finally counted under a light 
microscope. The experiment was performed in triplicate.
In Vivo functional study
Nude mice ectopic tumorigenesis model
MHCC97L cells (1 × 106 cells in 100ul saline) 
were injected subcutaneously into the right flank of the 
nude mice (6–8weeks, male) under anaesthesia with 
an intraperitoneal injection of pentobarbital. When 
the tumor developed, the size was measured every 
4 days for 3 weeks. The volume of the tumor was 
calculated as follows: tumor volume (mm3) = 1/2 × 
length × width2. Tumor weight was measured when the 
mice were sacrificed at 4 weeks after the injection of tumor 
cells. Tumor tissues were harvested for further analysis. 
Six mice were recruited for each of the experimental 
group. The study had been licensed according to Animal 
(Control of Experiments) Ordinance Chapter 340 by the 
Department of Health, Hong Kong Special Administrative 
Region. (ref.: (11–632) in DH/HA&P/8/2/3 Pt. 31).
Nude mice orthotopic xenograft liver  
cancer model
When the subcutaneous tumors grew and reached 
6mm × 6mm in size, the animals were sacrificed by an 
overdose intraperitoneal injection of pentobarbital. The 
tumor tissues were harvested and cut into 1–2mm3 cubes. 
The tumor tissue cubes were then implanted into the left 
liver lobes of another group of mice under anaesthesia as 
described previously [41]. Five weeks after the tumor 
implantation, the animals were sacrificed for samples 
collection and further analysis. Eight mice were recruited in 
each group. The study had been licensed according to Animal 
(Control of Experiments) Ordinance Chapter 340 by the 
Department of Health, Hong Kong Special Administrative 
Region. (ref.: (11–632) in DH/HA&P/8/2/3 Pt. 31).
Mechanism study
EMT detection
In order to explore the mechanism of anti-invasiveness 
of rGPx3, the role of rGPx3 in the EMT process was 
detected. EMT of MHCC97L was pre-induced by TGF-β 
in vitro and then treated with rGPx3. The epithelial and 
mesenchymal markers were detected afterwards. Five 
E-cadherin transcriptional repressors, Slug, Snail, SIP1, 
Zeb1 and Twist, which were commonly involved in the EMT 
process, were detected to identify which one was responsible 
for the inhibitory effect of rGPx3 on EMT. Details were 
listed in supplementary material.
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Regulation of NFκB signaling pathway
In order to explore whether the suppressive effect 
of rGPx3 on SIP1 was through inhibition of the NFκB 
signaling pathway, the activation of NFκB in MHCC97L 
was pre-induced by EGF and then treated with rGPx3. 
The nuclear translocation of NFκB was observed by 
immunoflorescence. To explore whether the down-
regulation of SIP1 could be directly regulated by the 
NFκB signaling pathway, NFκB inhibitor (pyrrolidine 
dithiocarbamate, PDTC, Sigma) was used. Details were 
listed in supplementary material.
Regulation of Erk signaling pathway
In order to investigate whether the inhibitory effect 
of rGPx3 on NFκB was through inhibition of Erk pathway, 
the activation of Erk was pre-induced in MHCC97L by 
EGF in vitro and then treated with rGPx3. To explore 
whether activation of NFκB could be directly regulated 
by Erk signaling pathway, Erk inhibitor (U0126) was used. 
Details were listed in supplementary material.
Regulation of MKP3 expression
In order to explore whether inhibitory effect of 
rGPx3 on Erk activation was through regulation of 
MKP3, expression of MKP3 were detected in MHCC97L 
after rGPx3 administration. To explore whether MKP3 
expression was regulated by ROS levels, different 
concentrations of H2O2 administration were applied. 
Details were listed in supplementary material.
Translational study
Establishment of engineered hiPSC-MSCs  
delivering GPx3
A full-length human GPx3 gene was transduced 
into expression plasmid pCDH-CMV-MCS-EF1-copGFP 
(System Biosciences, SBI). Virus particles were packaged 
in 293TN cells (System Biosciences, SBI). The hiPSC-
MSCs cell line was derived from our collaborator 
Dr. Lian [23]. Expression of GPx3 after transduction was 
confirmed by western-blot and Elisa. Stem cells’ property 
was investigated after transduction using flow cytometry. 
Antibodies of positive markers CD44-PE, CD105-PE, 
CD90-PE and CD73-PE and negative markers CD34-PE 
and CD45-PE were purchased from Biosciences (BD).
Investigation of tumor suppressive role  
of hiPSC-MSC-GPx3 in vitro
The effect of hiPSC-MSC-GPx3 on the proliferation 
of MHCC97L cells was examined by MTT assay. 
MHCC97L was co-cultured with hiPSC-MSC-GPx3 
at a different ratio for different time period. As 
hiPSC-MSC-GPx3 could hardly proliferate in the medium 
of MHCC97L, the OD value of MTT assay mainly reflects 
the proliferation of MHCC97L cells. In order to distinguish 
two types of cells in co-culture system, MHCC97L 
(1×104/well) was labeled with luciferin and co-cultured 
with hiPSC-MSC-GPx3 (5×103/well). Proliferation of 
MHCC97L in co-culture system was shown as luciferin 
signal detected by Xenogen IVIS® in vivo imaging system.
Investigation of tumor suppressive role of hiPSC-
MSC-GPx3 in vivo
The nude mice ectopic and orthotopic xenograft 
liver cancer models were established as described in 
section of in vivo functional study above. In the ectopic 
xenograft liver cancer model, MHCC97L (2×106/100µL) 
was co-injected with hiPSC-MSC-GPx3 (1×106/100µL) 
subcutaneously into the right flank of nude mice. 
Tumor size was measured every 5 days for 3 weeks. In 
orthotopic xenograft liver cancer model, hiPSC-MSC-
GPx3 (1×106/100µL) was injected directly into the spleen 
after implantation of a tumor nodule on the surface 
of liver. Kinetic images of tumor growth in vivo were 
captured by Xenogen IVIS® in vivo imaging system. 
Migrated hiPSC-MSCs in tumor tissues were detected by 
immuno-florescence (GFP) and IHC staining with anti-
human fibroblast anti-body DIA100 (Dianova, Germany). 
Expression of GPx3 was detected by IHC staining with 
anti-human GPx3 anti-body (Abcam).
Statistical analysis
The Chi-square test was used to compare categorical 
data. The T test was adopted to compare continuous 
variables. For mRNA level of GPx3 within tissues, 
2-fold difference was selected as cut-off point by which 
the patients could be segregated most evenly. Other 
cutoff points had also been taken into consideration and 
investigated. They showed the similar clinical implication. 
For plasma GPx3, The Youden index [42] was used to 
determine the optimal cutoff point for the prediction of 
five year recurrence. The cutoff point with the maximized 
Youden index showed the most optimal sensitivity and 
specificity for prediction. Kaplan-Meier survival analysis 
was performed to compare the survival outcome of HCC 
patients. The significant difference between survival 
outcomes was detected by the log–rank test. The Cox 
proportional hazard regression model was used to identify 
predictors for overall survival. The variables were selected 
into the final equation in multivariable analysis according 
to forward stepwise selection procedure. P < 0.05 was 
considered as statistically significant. Calculations were 
made using SPSS computer software version 16 (SPSS 
Inc, Chicago, IL, USA).
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